Analysts Assign Integra LifeSciences 'Reduce' Rating, Set Average $15 Target
Seven research firms covering Integra LifeSciences issued an average “Reduce” rating, with three analysts at sell, two at hold, and two at buy. The consensus 12-month price target stands at $15.00, while JPMorgan lifted its target to $13.00 and Citigroup trimmed its target to $11.00.
1. JPMorgan Healthcare Conference Presentation
At the 44th Annual J.P. Morgan Healthcare Conference, Integra LifeSciences outlined its financial outlook and recent operational priorities. Management confirmed Q4 2025 earnings-per-share guidance of 0.79–0.84 and full-year 2025 EPS guidance of 2.19–2.24, reiterating confidence in mid-single-digit top-line growth. Executives highlighted progress in neurosurgery product launches, including expanded adoption of new dural repair technologies, and noted ongoing clinical trials in regenerative medicine aimed at broadening the company’s wound-care portfolio.
2. Analyst Ratings Overview
MarketBeat data shows seven brokerages currently cover Integra LifeSciences, assigning an average rating of “Reduce.” Within that group, three firms carry sell recommendations, two maintain hold ratings and two cases are rated buy. Notable recent actions include a restated sell (e+) by Weiss Ratings, an upgrade to buy by Wall Street Zen, and underwriting changes by JPMorgan Chase & Co., Truist Financial and Citigroup, each adjusting outlooks and targets over the past quarter.
3. Third Quarter Performance
In its latest quarterly report, Integra LifeSciences delivered adjusted EPS of 0.54, surpassing consensus estimates by 0.11. Revenues totaled $402.1 million, marking a 5.6% year-over-year increase but falling short of analyst projections by $12.2 million. The company reported a negative net margin of 30.15% and achieved a 14.06% return on equity. Management attributed the top-line shortfall to modest procedural volume headwinds in cranial and spinal implant segments, offset by strength in advanced wound-care sales.
4. Insider and Institutional Activity
Director Jeffrey A. Graves increased his stake by acquiring 9,000 additional shares, raising his total ownership to 41,086 shares—a 28.05% increase. Insider holdings now represent 3.54% of outstanding shares. On the institutional side, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position by 5.1% to 40,441 shares, UBS Asset Management Americas increased its stake by 23.0% to 244,335 shares, and Goldman Sachs Group grew its holdings by 2.2% to 1,660,511 shares, reflecting continued confidence among major investors.